Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Sagimet Biosciences Inc.NASDAQ: SGMT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$357M, compared with -$313.49M a year earlier.
Context
- Retained earnings amounted to 331.3% of total assets at the end of Q1 FY2026, up 116.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -13.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (346.35M) USD
- Year-over-year change
- -17.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (346.35M) | -17.3% |
| FY2024 | 2024-12-31 | (295.31M) | -18.2% |
| FY2023 | 2023-12-31 | (249.74M) | -12.6% |
| FY2022 | 2022-12-31 | (221.87M) | -15.9% |
| FY2021 | 2021-12-31 | (191.37M) | — |
Retained Earnings vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 retained earnings of -$357M is the 4th highest of the 11 companies compared; the peer median is -$554.78M.
- Its year-over-year change of -13.9% is the 3rd highest of 11, against a peer median of -28.2%.
- Retained earnings amounts to 331.3% of total assets for SGMT, versus a peer median of 218.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | -$248.77M | -43.5% | — | 108.8% |
| Mar 2026 | -$270.39M | -23.8% | — | 816.8% | |
| Mar 2026 | -$312.81M | -113.2% | — | 93.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$357M | -13.9% | — | 331.3% |
| Mar 2026 | -$473.84M | -32.7% | — | 216.0% | |
| Mar 2026 | -$541.55M | -17.0% | — | 220.7% | |
| Mar 2026 | -$568.01M | -42.5% | — | 212.7% | |
| Mar 2026 | -$652.34M | -13.1% | — | 293.6% | |
| Mar 2026 | -$744.47M | -15.1% | — | 673.4% | |
| Mar 2026 | -$841.13M | -0.8% | — | 357.2% | |
| Mar 2026 | -$293.78B | -122645.6% | — | 136.8% | |
| Peer median (excluding SGMT) | -$554.78M | -28.2% | — | 218.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.